Lionel Rostaing

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4852059/publications.pdf

Version: 2024-02-01

129 papers	6,252 citations	147566 31 h-index	71532 76 g-index
134 all docs	134 docs citations	134 times ranked	5954 citing authors

#	Article	IF	Citations
1	Cryoglobulinemia and doubleâ€filtration plasmapheresis: Personal experience and literature review. Therapeutic Apheresis and Dialysis, 2023, 27, 159-169.	0.4	4
2	Immune responses following tocilizumab therapy to desensitize HLA-sensitized kidney transplant candidates. American Journal of Transplantation, 2022, 22, 71-84.	2.6	20
3	Age-adapted percentiles of measured glomerular filtration in healthy individuals: extrapolation to living kidney donors over 65Âyears. Clinical Chemistry and Laboratory Medicine, 2022, 60, 401-407.	1.4	7
4	Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study. Journal of the American Society of Nephrology: JASN, 2022, 33, 829-838.	3.0	23
5	Very Early Severe Posttransplant Recurrent Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis after Kidney Transplantation: Two Case Reports. Case Reports in Nephrology, 2022, 2022, 1-5.	0.2	2
6	Kidney Transplantation for Focal Segmental Glomerulosclerosis: Can We Prevent Its Recurrence? Personal Experience and Literature Review. Journal of Clinical Medicine, 2022, 11, 93.	1.0	1
7	Tocilizumab Trough Levels Variability in Kidney-Transplant Candidates Undergoing Desensitization. Journal of Clinical Medicine, 2022, 11, 91.	1.0	2
8	Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review. Frontiers in Immunology, 2022, 13, 839380.	2.2	9
9	Genomic Mutations of BK Polyomavirus in Patients after Kidney Transplantation: A Cross-Sectional Study in Vietnam. Journal of Clinical Medicine, 2022, 11, 2544.	1.0	2
10	The Mayo Adhesive Probability score can help predict intra- and postoperative complications in patients undergoing laparoscopic donor nephrectomy. World Journal of Urology, 2021, 39, 2775-2781.	1.2	5
11	Impact of Immunosuppressive Strategies on Postâ€“Kidney Transplantation Thrombocytopenia. Transplantation Proceedings, 2021, 53, 941-949.	0.3	1
12	Success of rheopheresis to treat digital hypoperfusion ischemic syndrome. Therapeutic Apheresis and Dialysis, 2021, 25, 362-364.	0.4	1
13	Isoagglutinin removal by plasma centrifugation or filtration (single or double): A prospective study in a single center. Journal of Clinical Apheresis, 2021, 36, 149-160.	0.7	4
14	Development and Validation of a Modified Full Age Spectrum Creatinine-Based Equation to Estimate Glomerular Filtration Rate. Annals of Internal Medicine, 2021, 174, 183-191.	2.0	157
15	pre-existing diabetes and PTDM in kidney transplant recipients: how to handle immunosuppression. Expert Review of Clinical Pharmacology, 2021, 14, 55-66.	1.3	7
16	Treatment of refractory myasthenia gravis by doubleâ€filtration plasmapheresis and rituximab: A case series of nine patients and literature review. Journal of Clinical Apheresis, 2021, 36, 348-363.	0.7	5
17	The effect of anemia on the efficacy and safety of treating chronic hepatitis C infection with direct-acting antivirals in patients with chronic kidney disease. International Urology and Nephrology, 2021, 53, 749-761.	0.6	5
18	Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis. International Urology and Nephrology, 2021, 53, 591-600.	0.6	1

#	Article	IF	Citations
19	Transplantation in the era of the Covidâ€19 pandemic: How should transplant patients and programs be handled?. Reviews in Medical Virology, 2021, 31, 1-9.	3.9	12
20	Temporal trends in living kidney donation in France between 2007 and 2017. Nephrology Dialysis Transplantation, 2021, 36, 730-738.	0.4	11
21	Comparison of three modalities of plasmapheresis on coagulation: Centrifugal, singleâ€membrane filtration, and doubleâ€filtration plasmapheresis. Journal of Clinical Apheresis, 2021, 36, 408-419.	0.7	6
22	A Case of <i>Pneumocystis jirovecii</i> Pneumonia under Belatacept and Everolimus: Benefit-Risk Balance between Renal Allograft Function and Infection. Case Reports in Nephrology and Dialysis, 2021, 11, 10-15.	0.3	1
23	Treatment of antibodyâ€mediated rejection with doubleâ€filtration plasmapheresis, low dose IVIg plus rituximab after kidney transplantation. Journal of Clinical Apheresis, 2021, 36, 584-594.	0.7	3
24	Apheresis Efficacy and Tolerance in the Setting of HLA-Incompatible Kidney Transplantation. Journal of Clinical Medicine, 2021, 10, 1316.	1.0	16
25	Fibrinogen reconstitution after therapeutic apheresis: Comparison of doubleâ€filtration plasmapheresis, plasma exchange, and immunoadsorption. Journal of Clinical Apheresis, 2021, 36, 574-583.	0.7	4
26	Marginal Impact of Tocilizumab Monotherapy on Anti-HLA Alloantibodies in Highly Sensitized Kidney Transplant Candidates. Transplantation Direct, 2021, 7, e690.	0.8	16
27	Atypical Evolution of Secondary Hemolytic Uremic Syndrome Defined as Paraneoplastic Syndrome under Eculizumab and Palbociclib Therapies. Case Reports in Oncology, 2021, 14, 676-680.	0.3	2
28	Living kidney donor evaluation for all candidates with normal estimated GFR for age. Transplant International, 2021, 34, 1123-1133.	0.8	3
29	Protocol Biopsies on de novo Renal-Transplants at 3 Months after Surgery: Impact on 5-Year Transplant Survival. Journal of Clinical Medicine, 2021, 10, 3635.	1.0	5
30	How to improve clotting factors depletion in doubleâ€filtration plasmapheresis. Journal of Clinical Apheresis, 2021, 36, 766-774.	0.7	1
31	Immortal Time-Biasâ€“Corrected Survival of Highly Sensitized Patients and HLA-desensitized Kidney Transplant Recipients. Kidney International Reports, 2021, 6, 2629-2638.	0.4	9
32	Immune Response Postâ€“SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept. Transplantation, 2021, 105, e259-e260.	0.5	22
33	Adverse effects of immunosuppression after liver transplantation. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2021, 54-55, 101762.	1.0	15
34	Tocilizumab and Desensitization in Kidney Transplant Candidates: Personal Experience and Literature Review. Journal of Clinical Medicine, 2021, 10, 4359.	1.0	10
35	Early Steroid Withdrawal After Kidney Transplantation in Patients at Risk for New-Onset Diabetes After Transplantation. Transplantation Proceedings, 2021, 53, 2216-2226.	0.3	0
36	Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine Response. Journal of Clinical Medicine, 2021, 10, 5159.	1.0	12

#	Article	IF	Citations
37	Conversion from Calcineurin Inhibitorâ€“ to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 3252-3264.	3.0	41
38	Tocilizumab in the Treatment of Chronic Antibody-Mediated Rejection Post Kidney Transplantation: Clinical and Histological Monitoring. Frontiers in Medicine, 2021, 8, 790547.	1.2	11
39	Immunoadsorption for Recurrent Primary Focal Segmental Glomerulosclerosis on Kidney Allografts: A Single-Center Experience and Literature Review. Blood Purification, 2020, 49, 322-333.	0.9	8
40	The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentrationâ€“Dose Ratio on Death-censored Graft Survival. Transplantation, 2020, 104, 1263-1271.	0.5	39
41	Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience. Transplantation Proceedings, 2020, 52, 3179-3185.	0.3	3
42	Effect of immunoadsorption alone or combined with membrane filtration on hemostasis parameters. Journal of Clinical Apheresis, 2020, 35, 444-452.	0.7	5
43	Prospects for improved glomerular filtration rate estimation based on creatinineâ€”results from a transnational multicentre study. CKJ: Clinical Kidney Journal, 2020, 13, 674-683.	1.4	11
44	Opportunistic Infections and Efficacy Following Conversion to Belatacept-Based Therapy after Kidney Transplantation: A French Multicenter Cohort. Journal of Clinical Medicine, 2020, 9, 3479.	1.0	17
45	Predonation Single Kidney Glomerular Filtration Rate in Living Kidney Transplantation to Predict Graft Function and Donor Functional Gain. Transplantation Proceedings, 2020, 52, 712-721.	0.3	2
46	Should kidney allografts from old donors be allocated only to old recipients?. Transplant International, 2020, 33, 849-857.	0.8	12
47	Where do we stand in 2020 regarding induction therapy after kidney transplantation?. Transplant International, 2020, 33, 858-862.	0.8	1
48	Why the immune system fails to mount an adaptive immune response to a COVIDâ€19 infection. Transplant International, 2020, 33, 824-825.	0.8	124
49	Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives. Transplantation Reviews, 2020, 34, 100531.	1.2	17
50	Baseline antiâ€CMV cellular immunity is similar between patients with a kidney transplant or receiving hemodialysis. Transplant International, 2020, 33, 961-962.	0.8	1
51	Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters. Transplantation Direct, 2020, 6, e517.	0.8	9
52	Why the immune system fails to mount an adaptive immune response to a COVID-19 infection. , 2020, 33, 824.		1
53	Comparison of graft and patient survival according to the transplantation centre policy for 1-year screening biopsy among stable kidney recipients: a propensity score-based study. Nephrology Dialysis Transplantation, 2019, 34, 703-711.	0.4	9
54	Hemodialysis coupled with rheopheresis in calciphylaxis: A winning combination. Journal of Clinical Apheresis, 2019, 34, 631-633.	0.7	4

#	Article	IF	Citations
55	Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality. International Urology and Nephrology, 2019, 51, 1639-1647.	0.6	5
56	High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents. International Urology and Nephrology, 2019, 51, 2243-2254.	0.6	5
57	Apheresis Therapy for Steroid-Resistant Idiopathic Nephrotic Syndrome: Report on a Case Series. Case Reports in Nephrology, 2019, 2019, 1-4.	0.2	1
58	Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients. International Urology and Nephrology, 2019, 51, 2295-2304.	0.6	5
59	Belatacept in kidney transplantation and its limitations. Expert Review of Clinical Immunology, 2019, 15, 359-367.	1.3	32
60	An Atypical Case of Shiga Toxin Producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) in a Lung Transplant Recipient. Case Reports in Transplantation, 2019, 2019, 1-3.	0.1	2
61	Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol. Transplant Immunology, 2019, 56, 101207.	0.6	11
62	Effects of immunoadsorption combined with membrane filtration on complement markers â€“ results of a randomized, controlled, crossover study. Transplant International, 2019, 32, 876-883.	0.8	5
63	An update on the safety of tacrolimus in kidney transplant recipients, with a focus on tacrolimus minimization. Expert Opinion on Drug Safety, 2019, 18, 285-294.	1.0	34
64	Dynamic predictions of long-term kidney graft failure: an information tool promoting patient-centred care. Nephrology Dialysis Transplantation, 2019, 34, 1961-1969.	0.4	13
65	Impact of estimation versus direct measurement of predonation glomerular filtration rate on the eligibility of potential living kidney donors. Kidney International, 2019, 95, 896-904.	2.6	31
66	Early Prediction of Graft Outcomes After Kidney Transplantation From Donors After Circulatory Death: Biomarkers and TransplantationÂCharacteristics. Transplantation Proceedings, 2019, 51, 3234-3243.	0.3	3
67	Outcomes at 7Âyears postâ€transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in <scp>BENEFIT</scp> and <scp>BENEFIT</scp>â€<scp>EXT</scp>. Clinical Transplantation, 2018, 32, e13225.	0.8	8
68	Renal complications of liver diseases. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1135-1142.	1.4	9
69	Tailoring tacrolimus therapy in kidney transplantation. Expert Review of Clinical Pharmacology, 2018, 11, 581-588.	1.3	19
70	AdvagrafÂ® with or without an induction therapy for de novo kidney-transplant recipients. Expert Review of Clinical Immunology, 2018, 14, 461-467.	1.3	3
71	Reducing Fibrinogen and Factor XIII Using Double-Filtration Plasmapheresis for Antibody-Mediated Rejection: Predictive Models. Blood Purification, 2018, 46, 239-245.	0.9	9
72	Negative Impact of CMV and BKV Infections on Kidney-Allograft Function at 1-Year Post-Transplantation: Can it Be Changed by Modifying Immunosuppression?. EBioMedicine, 2018, 34, 2-3.	2.7	9

#	Article	IF	Citations
73	The age-calibrated measured glomerular filtrationÂrate improves living kidney donationÂselection process. Kidney International, 2018, 94, 616-624.	2.6	28
74	Desensitization in the Setting of HLA-Incompatible Kidney Transplant. Experimental and Clinical Transplantation, 2018, 16, 367-375.	0.2	6
75	Novel approaches to improve recipient and allograft outcomes. Nature Reviews Nephrology, 2017, 13, 73-74.	4.1	6
76	New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients. Expert Opinion on Drug Safety, 2017, 16, 845-855.	1.0	9
77	ADHERE: randomized controlled trial comparing renal function inde novokidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus. Transplant International, 2017, 30, 83-95.	0.8	18
78	Successful Transplantation in ABOâ€•and HLAâ€Incompatible Living Kidney Transplant Patients: A Report on 12 Cases. Therapeutic Apheresis and Dialysis, 2016, 20, 507-516.	0.4	10
79	Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia. Transplant International, 2016, 29, 315-322.	0.8	21
80	<scp>LCPT</scp>onceâ€daily extendedâ€release tacrolimus tablets versus twiceâ€daily capsules: a pooled analysis of two phase 3 trials in importantde novoand stable kidney transplant recipient subgroups. Transplant International, 2016, 29, 603-611.	0.8	25
81	Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients. Transplant International, 2016, 29, 1257-1265.	0.8	11
82	Costimulation Blockade in Kidney Transplantation. Transplantation, 2016, 100, 2315-2323.	0.5	36
83	Costimulation Blockade in Kidney Transplantation. Transplantation, 2016, 100, 2516-2518.	0.5	4
84	Belatacept and Long-Term Outcomes in Kidney Transplantation. New England Journal of Medicine, 2016, 374, 333-343.	13.9	593
85	Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. American Journal of Kidney Diseases, 2016, 67, 648-659.	2.1	78
86	Place of mTOR inhibitors in management of BKV infection after kidney transplantation. Journal of Nephropathology, 2016, 5, 1-7.	0.1	26
87	Early post-transplant complications following ABO-incompatible kidney transplantation. Journal of Nephropathology, 2016, 5, 19-27.	0.1	7
88	Treatment of large plasma volumes using specific immunoadsorption to desensitize ABO-incompatible kidney-transplant candidates. Journal of Nephropathology, 2016, 5, 90-97.	0.1	16
89	Immunoadsorption and Hemodialysis as a Tandem Procedure: A Single-Center Experience of More than 60 Procedures. International Journal of Artificial Organs, 2015, 38, 304-310.	0.7	12
90	Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. Journal of Transplantation, 2015, 2015, 1-5.	0.3	5

#	Article	IF	Citations
91	Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. BMJ, The, 2015, 351, h3557.	3.0	146
92	Temporal evolution of the distribution of hepatitis E virus genotypes in Southwestern France. Infection, Genetics and Evolution, 2015, 35, 50-55.	1.0	33
93	Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation. Transplant International, 2015, 28, 255-258.	0.8	22
94	The safety of calcineurin inhibitors for kidney-transplant patients. Expert Opinion on Drug Safety, 2015, 14, 1531-1546.	1.0	66
95	Hepatitis E virus: Chronic infection, extra-hepatic manifestations, and treatment. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 20-27.	0.7	78
96	Each additional hour of cold ischemia time significantly increases the risk of graft failure and mortality following renal transplantation. Kidney International, 2015, 87, 343-349.	2.6	287
97	Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage. Journal of Nephropathology, 2015, 4, 110-5.	0.1	13
98	Epidemiology of chronic kidney diseases in the Republic of Guinea; future dialysis needs. Journal of Nephropathology, 2015, 4, 127-33.	0.1	5
99	Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates. Experimental and Clinical Transplantation, 2015, 13 Suppl 1, 201-6.	0.2	2
100	An Association between BK Virus Replication in Bone Marrow and Cytopenia in Kidney-Transplant Recipients. Journal of Transplantation, 2014, 2014, 1-9.	0.3	7
101	Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate. Case Reports in Transplantation, 2014, 2014, 1-4.	0.1	8
102	Incidence of anti-HLA donor specific antibodies in liver-transplant patients given mTOR inhibitors without calcineurin inhibitors. Journal of Hepatology, 2014, 61, 963-965.	1.8	8
103	A useful scoring system for the prediction and management of delayed graft function following kidney transplantation from cadaveric donors. Kidney International, 2014, 86, 1130-1139.	2.6	82
104	What are the Management Issues for Hepatitis C in Dialysis Patients?. Seminars in Dialysis, 2014, 27, 451-455.	0.7	2
105	Isolated Aspergillosis Myocardial Abscesses in a Liver-Transplant Patient. Case Reports in Transplantation, 2014, 2014, 1-3.	0.1	5
106	Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients. New England Journal of Medicine, 2014, 370, 1111-1120.	13.9	436
107	A prospective study in male recipients of kidney transplantation reveals divergent patterns for inhibin B and testosterone secretions. Basic and Clinical Andrology, 2014, 24, 11.	0.8	9
108	Prospective monitoring of cytomegalovirus, Epstein-Barr virus, BK virus, and JC virus infections on belatacept therapy after a kidney transplant. Experimental and Clinical Transplantation, 2014, 12, 212-9.	0.2	10

#	Article	IF	Citations
109	Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibodyâ€mediated disease. British Journal of Clinical Pharmacology, 2013, 76, 734-740.	1.1	68
110	Hepatitis C virus infection in nephrology patients. Journal of Nephropathology, 2013, 2, 217-33.	0.1	11
111	Hepatitis E Virus and the Kidney in Solid-Organ Transplant Patients. Transplantation, 2012, 93, 617-623.	0.5	170
112	Do kidney histology lesions predict longâ€term kidney function after liver transplantation?. Clinical Transplantation, 2012, 26, 927-934.	0.8	6
113	Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation. Transplant International, 2012, 25, e62-e66.	0.8	43
114	Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transplant International, 2012, 25, 592-602.	0.8	104
115	Belatacept-versusCyclosporine-Based Immunosuppression in Renal Transplant Recipients with Pre-existing Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2696-2704.	2.2	30
116	Switching from Calcineurin Inhibitor-based Regimens to a Belatacept-based Regimen in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 430-439.	2.2	158
117	No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transplant International, 2010, 23, 594-601.	0.8	54
118	Influence of Immunosuppressive Therapy on the Natural History of Genotype 3 Hepatitis-E Virus Infection After Organ Transplantation. Transplantation, 2010, 89, 353-360.	0.5	201
119	Population Pharmacokinetics and Bayesian Estimation of Tacrolimus Exposure in Renal Transplant Recipients on a New Once-Daily Formulation. Clinical Pharmacokinetics, 2010, 49, 683-692.	1.6	81
120	Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial. Liver Transplantation, 2009, 15, 1262-1269.	1.3	137
121	Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients. New England Journal of Medicine, 2008, 358, 811-817.	13.9	1,197
122	Treatment of Hepatitis C Virus Infection (HCV) After Renal Transplantation: Implications for HCV-Positive Dialysis Patients Awaiting a Kidney Transplant. Transplantation, 2006, 82, 853-856.	0.5	61
123	Corticosteroid-Free Immunosuppression with Tacrolimus, Mycophenolate Mofetil, and Daclizumab Induction in Renal Transplantation. Transplantation, 2005, 79, 807-814.	0.5	217
124	Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient. American Journal of Kidney Diseases, 2005, 45, 193-196.	2.1	55
125	Natural History of Hepatitis C Virus-Related Liver Fibrosis After Renal Transplantation. American Journal of Transplantation, 2005, 5, 1704-1712.	2.6	119
126	Amantadine therapy in renal transplant patients with hepatitis C virus infection. Journal of Clinical Virology, 2004, 30, 110-114.	1.6	39

#	Article	IF	Citations
127	Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. American Journal of Kidney Diseases, 2003, 42, 184-192.	2.1	83
128	Evidence that Clearance of Hepatitis C Virus RNA after Î±-Interferon Therapy in Dialysis Patients Is Sustained after Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2003, 14, 2092-2098.	3.0	173
129	TREATMENT OF CHRONIC HEPATITIS C WITH RECOMBINANT INTERFERON ALPHA IN KIDNEY TRANSPLANT RECIPIENTS. Transplantation, 1995, 59, 1426-1431.	0.5	186